Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioMarin Pharmaceutical, a US based developer of biopharmaceuticals, has started BMN 673 Phase 1 trial in patients who are suffering from advanced hematological malignancies.
Subscribe to our email newsletter
The open-label, two-arm dose escalation trial intends to establish the maximum tolerated dose of BMN 673.
The trial will also evaluate the pharmacodynamics, pharmacokinetics, safety and preliminary efficacy of the drug in patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).
The study expects to recruit around 80 patients in the US and UK.
BioMarin chief medical officer Hank Fuchs said the approach to the development of their PARP inhibitor is to identify tumor mutations that are more susceptible to treatment with BMN 673 and to target subgroups based on the genetic basis of the disease.
"We are committed to the advancement of our pipeline and look forward to many clinical milestones over the next 18 months," Fuchs said.